Pharmaceutical Mail. A few weeks ago, the Spanish biosimilar employers' association, Biosim, was founded, chaired by the CEO of Sandoz, Joaquín Rodrigo. As I already told mailfarmaceutico.com, his first request to the Administration is clear: "Specific legislation through which these medicines are treated with all their singularity" and that facilitates the biosimilar becoming a "tool of access for patients and sustainability in the short, medium and long term'.